S Ellermann-Eriksen Selected Research

Antibodies

6/2000

Inhibition of NO production in macrophages by IL-13 is counteracted by Herpes simplex virus infection through tumor necrosis factor-alpha-induced activation of NK-kappa B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

S Ellermann-Eriksen Research Topics

Disease

6	Infections 07/2016 - 01/2000
2	Herpes Simplex 09/2012 - 06/2000
2	Necrosis 06/2000 - 01/2000
2	Virus Diseases (Viral Diseases) 06/2000 - 01/2000
1	Human Influenza (Influenza) 09/2012
1	Sepsis (Septicemia) 11/2008
1	Pneumonia (Pneumonitis) 02/2001

Drug/Important Bio-Agent (IBA)

3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2001 - 01/2000
2	Anti-Bacterial Agents (Antibiotics)IBA 07/2016 - 11/2008
1	Interleukin-6 (Interleukin 6)IBA 11/2008
1	Dactinomycin (Actinomycin)FDA LinkGeneric 08/2001
1	Proteins (Proteins, Gene)FDA Link 08/2001
1	Messenger RNA (mRNA)IBA 08/2001
1	Dexamethasone (Maxidex)FDA LinkGeneric 02/2001
1	ZymosanIBA 02/2001
1	AntibodiesIBA 06/2000
1	Interleukin-13IBA 06/2000
1	STAT6 Transcription FactorIBA 06/2000
1	NF-kappa B (NF-kB)IBA 01/2000
1	InterferonsIBA 01/2000
1	InterleukinsIBA 01/2000
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2000
1	Interleukin-4 (Interleukin 4)IBA 01/2000
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2000

Therapy/Procedure

1	Urinary Catheters 07/2016
1	Tonsillectomy 09/2012